多发性骨髓瘤中的可溶性B细胞成熟抗原
本文综述可溶性B细胞成熟抗原(sBCMA)在多发性骨髓瘤(MM)中的应用。sBCMA由γ-分泌酶切割产生,可通过电化学发光、荧光、酶联免疫吸附及质谱蛋白质组学等方法检测。多项研究提示sBCMA可用于癌前浆细胞疾病风险分层、MM诊断与预后判断及抗骨髓瘤治疗后的疗效评估。
要点
- sBCMA由γ-分泌酶切割BCMA产生,可在血清/血浆中定量检测。
- sBCMA半衰期短且不依赖肾功能,对非分泌型或寡分泌型MM监测有优势。
- 多项研究提示sBCMA可用于癌前浆细胞疾病风险分层、MM诊断与预后及疗效评估。
核心结论
- sBCMA可能是MM实验室检测的「瑞士军刀」,但其是否已准备好进入常规临床应用尚待明确。
研究设计与样本
- 本文为综述,汇总sBCMA在多发性骨髓瘤管理中的检测方法与临床研究证据。
主要发现
- sBCMA是BCMA经γ-分泌酶切割产生的截短形式,可在MM患者血清/血浆样本中通过电化学发光、荧光或酶联免疫吸附试验以及基于质谱的蛋白质组学进行定量。
- sBCMA血清半衰期短且不依赖肾功能,对非分泌型或寡分泌型MM患者的监测是可靠且便利的工具。
- 多项研究提示sBCMA在癌前浆细胞疾病风险分层、MM诊断与预后判断及抗骨髓瘤治疗后的疗效评估方面具有潜在用途。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
B-cell maturation antigen (BCMA) has emerged as a promising immunotherapeutic target in multiple myeloma (MM) management, with the successive approval of antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor T-cell therapies directed to this membrane receptor. Soluble BCMA (sBCMA), a truncated version produced through gamma-secretase cleavage, can be quantified in serum/plasma samples from patients with MM via electrochemiluminescence, fluorescence, or enzyme-linked immunosorbent assays, as well as through mass spectrometry-based proteomics. Besides its short serum half-life and independence from kidney function, sBCMA represents a reliable and convenient tool for MM monitoring in patients with nonsecretory or oligosecretory disease. Numerous studies have suggested a potential utility of this bioanalyte in the risk stratification of premalignant plasma cell disorders, diagnosis and prognostication of MM, and response evaluation following anti-myeloma therapies. In short, sBCMA might be the "Swiss army knife" of MM laboratory testing, but is it ready for prime time?
引用
- Costa BA, Ortiz RJ, Lesokhin AM, et al. Soluble B-cell maturation antigen in multiple myeloma. Am J Hematol. 2024. PMID: 38270277. doi:10.1002/ajh.27225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。